Dr Reddys Laboratories Stock Today

RDY Stock  USD 70.84  0.86  1.20%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 3

 
High
 
Low
Very Low
Dr Reddys is trading at 70.84 as of the 19th of June 2024; that is -1.2 percent decrease since the beginning of the trading day. The stock's open price was 71.7. Dr Reddys has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Dr Reddys Laboratories are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of March 2023 and ending today, the 19th of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of April 2001
Category
Healthcare
Classification
Health Care
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 166.54 M outstanding shares of which 867.9 K shares are at this time shorted by investors with about 4.11 days to cover. More on Dr Reddys Laboratories

Moving against RDY Stock

  0.65DSGN Design TherapeuticsPairCorr
  0.5VALN Valneva SE ADR Earnings Call This WeekPairCorr
  0.34VCYT VeracytePairCorr
  0.31ME 23Andme HoldingPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

RDY Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOMARC KIKUCHI
Thematic Ideas
(View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Obamacare, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.150.1437
Sufficiently Up
Slightly volatile
Asset Turnover0.780.7204
Significantly Up
Pretty Stable
Gross Profit Margin0.440.5861
Way Down
Pretty Stable
Total Current Liabilities69.8 B96 B
Way Down
Pretty Stable
Non Current Liabilities Total20.2 B10.9 B
Way Up
Slightly volatile
Total Assets214.9 B387.5 B
Way Down
Very volatile
Total Current Assets127.1 B248 B
Way Down
Very volatile
Total Cash From Operating Activities47.7 B45.4 B
Sufficiently Up
Slightly volatile
Dr Reddys can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dr Reddys' financial leverage. It provides some insight into what part of Dr Reddys' total assets is financed by creditors.
Liquidity
Dr Reddys Laboratories has 20.02 B in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. Dr Reddys Laboratories has a current ratio of 1.94, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for RDY to invest in growth at high rates of return.

Change In Working Capital

(22.46 Billion)
Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA. It is located in 8-2-337, Road No. 3, Hyderabad, India, 500034 and employs 27,048 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 11.98 B. Dr Reddys Laboratories runs under Pharmaceuticals sector within Health Care industry. The entity has 166.54 M outstanding shares of which 867.9 K shares are at this time shorted by investors with about 4.11 days to cover. Dr Reddys Laboratories has about 2.93 B in cash with 45.43 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 208.58.
Check Dr Reddys Probability Of Bankruptcy
Ownership Allocation
Dr Reddys Laboratories secures a total of 166.54 Million outstanding shares. About 85.0 % of Dr Reddys outstanding shares are held by general public with 15.01 (percent) by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check RDY Ownership Details

RDY Stock Institutional Holders

InstituionRecorded OnShares
Man Group Plc2024-03-31
705.6 K
Gqg Partners Llc2024-03-31
437 K
Grantham, Mayo, Van Otterloo & Co., Llc2024-03-31
338.8 K
Fisher Asset Management, Llc2024-03-31
318.4 K
Jpmorgan Chase & Co2024-03-31
260.1 K
Schroder Investment Management Group2024-03-31
222.7 K
Millennium Management Llc2024-03-31
206 K
Acadian Asset Management Llc2024-03-31
196.2 K
Ameriprise Financial Inc2024-03-31
185.6 K
Blackrock Inc2024-03-31
2.2 M
Royal Bank Of Canada2024-03-31
2.2 M
View Dr Reddys Diagnostics

Dr Reddys Historical Income Statement

At this time, Dr Reddys' Other Operating Expenses is fairly stable compared to the past year. EBIT is likely to rise to about 69.5 B in 2024, whereas Depreciation And Amortization is likely to drop slightly above 7.5 B in 2024. View More Fundamentals

RDY Stock Against Markets

Dr Reddys Corporate Directors

Leo PuriNon-Executive Independent DirectorProfile
Allan ObermanNon-Executive Independent DirectorProfile
Prasad MenonLead Non-Executive Independent DirectorProfile
Shikha SharmaNon-Executive Independent DirectorProfile

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.